Similarly, during a phase II clinical trial involving patients with stage IV non-small cell lung cancer (NSCLC) tumors carrying loss-of-function mutations in KEAP1 (KEAPSAKE trial, NCT04265534), CB-839 did not show advantageous effects compared to standard-of-care immunotherapy. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.